52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Kobayashi Pharmaceutical Co Ltd Says To Buy Back Up To 1.64 Percent Of Own Shares Worth 8 Billion Yen Through Aug. 31
Kobayashi Pharmaceutical in deal to buy cosmetics firm True Nature
R&I affirms Kobayashi Pharmaceutical's rating at "A" and says stable outlook -R&I
KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.
KDX Kobayashi Doshomachi Bldg.
4-4-10, Dosho-machi, Chuo-ku
Chairman of the Board, Chairman of Subsidiary, Representative Director
President, Executive Officer, Representative Director
Vice Chairman of the Board, Representative Director
Senior Managing Director, Executive Officer, Chief Senior Director of Group Main Office
Managing Director, Executive Officer, Chief Director of Sales
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* Says it will distribute 850,000 shares of its treasury common stock at 1 yen per share through private placement to The Master Trust Bank of Japan, Ltd.
* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I
Kobayashi Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 3 months ended 3 months ended Year to Mar 31, 2017 Jun 30, 2016 Dec 31, 2017 LATEST LATEST RESULTS RESULTS FORECAST Sales 30.75 36.77 150.00 Operating 4.96 7.30 20.00...
* Says it will retire 3 million shares (3.5 percent stake) of its common stock on Feb. 17
Kobayashi Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended Year ended Year to NEXT Dec 31, 2016 Mar 31, 2016 Dec 31, 2017 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 120.05 137.21...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.